Systematic review: adverse drug events with ipragliflozin
- PDF / 169,751 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 13 Downloads / 217 Views
1
Systematic review: adverse drug events with ipragliflozin In patients with type 2 diabetes mellitus, treatment with ipragliflozin is associated with an increased rate of genital infections compared with placebo, according to the results of a systematic review and meta-analysis reported in Advances in Therapy, and possibly an increased rate of hypoglycaemia. A search of ClinicalTrials.gov, MEDLINE, EMBASE and Cochrane Central revealed 8 randomised trials published in English involving patients who received ipragliflozin (n=1069) or placebo (n=450). Compared with placebo recipients, the incidence of drug-related adverse events was not significantly different in ipragliflozin recipients (risk ratio [RR] 1.04; 95% CI 0.69, 1.58), including those which led to drug discontinuation (RR 1.09; 0.57, 2.10). The risk of genital infection was significantly increased (RR 4.53; 1.48, 13.85; p=0.008). The risk of hypoglycaemia was also increased (RR 1.68; 1.03, 2.74; p=0.04), although the authors note that this result was influenced by one study, and that "hypoglycaemia might actually not have been significantly higher" in ipragliflozin recipients. There were no significant between-group differences for urinary tract infection, nasopharyngitis, constipation, dizziness, or gastrointestinal disorders. "Our results showed significantly higher genital infection rates to be associated with the use of ipragliflozin", note the authors, "which makes the usefulness of this treatment doubtful". Liu D, et al. Adverse Drug Events Observed with the Novel Sodium/Glucose Co-Transporter 2 Inhibitor Ipragliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Studies. Advances in Therapy : 26 Aug 2020. Available from: URL: http://doi.org/10.1007/ 803500767 s12325-020-01471-2
0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Sep 2020 No. 1821
Data Loading...
